Related Experiment Video

Updated: Jan 18, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.8K

BRAF mutations in ovarian cancer: immune microenvironment and therapeutic advances

Yuhang Wang1, Xue Du2

  • 1Graduate School, Tianjin Medical University, Tianjin, 300070, China.

Journal of Molecular Histology
|September 12, 2025
PubMed

Insights

BRAF mutations impact the ovarian cancer immune microenvironment, influencing prognosis and targeted therapy. Understanding this relationship is key for developing new ovarian cancer treatments.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Ovarian cancer is a lethal malignancy with poor prognosis.
  • BRAF mutations are implicated in oncogenic signaling and targeted therapy across cancers.
  • The tumor immune microenvironment critically influences tumor initiation and progression.

Purpose of the Study:

  • To review the impact of BRAF mutations on the ovarian cancer immune microenvironment.
  • To summarize recent advances in understanding BRAF mutations in ovarian cancer.
  • To assess the clinical significance for therapeutic strategies.

Main Methods:

  • Literature review of studies on BRAF mutations and ovarian cancer.
  • Analysis of the role of BRAF in oncogenic pathways.
  • Evaluation of the tumor immune microenvironment in ovarian cancer.

Main Results:

  • BRAF mutations influence immune cell infiltration and function within the ovarian tumor microenvironment.
  • Specific BRAF alterations correlate with distinct immune profiles.
  • These findings highlight the interplay between genetic mutations and anti-tumor immunity.

Conclusions:

  • BRAF mutations represent a significant factor modulating the ovarian cancer immune microenvironment.
  • Targeting BRAF may offer novel therapeutic avenues by altering immune responses.
  • Further research is warranted to translate these findings into clinical practice for ovarian cancer patients.
Keywords:
BRAF geneOvarian cancerTreatment strategiesTumor immunityTumor microenvironment

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.2K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K